Ping An Biomedical Co., Ltd. (PASW) is a Hong Kong–based micro-cap company, not an ETF. Formerly known as Majestic Ideal Holdings Ltd., it provides apparel supply-chain management services and has signaled a strategic pivot toward healthcare and biomedical technology. With essentially no credible analyst coverage, its $1.50 price objective comes from public discussion and technical context rather than a Wall Street consensus.
PASW has no meaningful sell-side coverage. Market data providers report no consensus price target for the stock, and the scattered figures that appear on aggregator sites are contradictory or unattributed and should not be treated as research. Because no credible analyst-derived mean or range exists, this article uses the fallback approach: a realistic price objective that is actually discussed publicly.
The $1.50 figure is a technical and psychological recovery objective. After a 1-for-40 reverse stock split took effect in October 2026, the shares initially repriced well above $1.00 before retreating toward roughly $1.10, with a recent prior close near $1.35 and intraday trading up to about $1.49. A move back toward $1.50 would represent a return to and modest extension of that post-split range, while placing meaningful distance above the $1.00 minimum bid threshold. This is a recovery scenario, not an analyst price target, and it is presented as context rather than a forecast.
As of early November 2026, PASW traded near $1.10, giving it a market capitalization of only a few million dollars. Reaching $1.50 would require a move of roughly 36%, a substantial gain for any security and especially large relative to the stock's thin float and negative EPS (earnings per share).
The path toward $1.50 is less about fundamentals and more about capital-structure mechanics and sentiment. The reverse split was designed to lift the bid price above Nasdaq's $1.00 threshold; sustaining that level for ten consecutive trading days would restore compliance. A genuine recovery toward $1.50 would depend on the company demonstrating progress on its healthcare repositioning and on investor appetite for a highly speculative micro-cap that remains loss-making.
The most durable reference points are structural rather than indicator-driven. The $1.00 level is the key threshold because Nasdaq's minimum bid requirement centers on it. Above the recent price near $1.10, the prior close around $1.35 and the recent intraday high near $1.49 form near-term resistance, with the $1.50 objective sitting just above that zone. The stock's split-adjusted 52-week range is exceptionally wide, reflecting both the reverse split and a sharp prior decline, which means historical levels offer limited predictive value.
Because there is no analyst coverage, no formal research horizon applies. The practical horizon is tied to the Nasdaq compliance calendar and the company's disclosure cadence. Investors should watch the company's next filings and earnings, any announcement on regained or lost compliance, further reverse splits or capital raises, progress on the healthcare pivot, and changes in the public float. None of these yields a definitive outcome, and the target remains a recovery scenario rather than a base case.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, thinly traded name like PASW, such tools can help traders spot changing trends and manage positions more efficiently without relying on guesswork. Traders can use these signals to discover opportunities, monitor holdings, and stay ahead of momentum shifts across the market.
The question of whether Ping An Biomedical (PASW) can reach $1.50 cannot be answered with a simple yes or no. The $1.50 objective is a recovery target drawn from the Nasdaq minimum-bid situation and the stock's post-reverse-split trading range, not from analyst research. It requires a substantial move of roughly 36% from recent levels. The reverse split and the healthcare narrative provide the clearest support, while delisting risk, potential dilution, persistent losses, and a thin float are the principal obstacles. With no analyst consensus to anchor expectations, investors should focus on compliance milestones, capital-structure changes, and the credibility of the company's strategic pivot before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that PASW and UFI have been poorly correlated (+13% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PASW and UFI's prices will move in lockstep.
| Ticker / NAME | Correlation To PASW | 1D Price Change % | ||
|---|---|---|---|---|
| PASW | 100% | -17.78% | ||
| UFI - PASW | 13% Poorly correlated | +1.90% | ||
| CULP - PASW | 12% Poorly correlated | -1.65% | ||
| AIN - PASW | 2% Poorly correlated | -1.56% |
| Ticker / NAME | Correlation To PASW | 1D Price Change % |
|---|---|---|
| PASW | 100% | -17.78% |
| Textiles industry (5 stocks) | 58% Loosely correlated | +4.31% |
| Process Industries industry (164 stocks) | -6% Poorly correlated | +0.54% |